immune response news from FierceBiotech
News
Transgene to partner after cancer vax passes trial
France's Transgene is taking the wraps off of positive Phase IIb data for its experimental cancer vaccine, TG4010. The European trial of 148 patients saw progression-free survival of 44 percent of Read more...
Novartis reports strong meningitis vaccine response
In a head-to-head trial, researchers for Novartis say that the experimental meningitis vaccine Menveo produced a more potent immune response than the standard therapy in use. And other data has Read more...
ALSO NOTED: Antisoma gets $25M milestone; Takeda pays out retention bonuses; and much more...
> Novartis has kicked off a late-stage trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer, triggering a $25 million milestone payment to Antisoma. Read more...
ALSO NOTED: Crucell shares up on TB data; Celera, Merck ink cancer deal; and much more...
> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the Read more...
Oxford BioMedica benefits from TroVax results
Oxford BioMedica shares were boosted by the news that its first mid-stage trial of Read more...
Genitope suspends cancer work, looks to alternatives
After reviewing a failed late-stage trial of MyVax for Hodgkins lymphoma, Genitope has decided to suspend development work and focus on alternatives like its antibody program. MyVax had already Read more...
SPOTLIGHT: Cold feet at FDA over Cervarix?
The prospect of approving Cervarix for a broad audience in the U.S. may be leading to a bad case of cold feet at the FDA. The agency's Office of Vaccine Research & Review deputy director Read more...
Sanaria takes new approach for malaria vaccine
The New York Times profiles Sanaria, a Maryland vaccines company that is taking a cue from Read more...
Merck, Dynavax ink $136M deal on hep B therapy
Merck has agreed to put up $31.5 million as a down payment for the worldwide rights to Dynavax Technologies' Read more...
New malaria vaccine offers better protection
Sanaria is grabbing headlines with its approach to fighting malaria. Researchers for the company have developed a process to create weakened parasites that create an immune response sufficient to Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets